| AAV9 | Adeno-Associated Virus serotype 9 |
| ABEmax-VRQR-SpCas9 | Advanced gene-editing system generally explained as an Optimized Adenine Base Editor (ABEmax) that utilizes a variant (VRQR) of the Streptococcus pyogenes Cas9 (SpCas9) enzyme |
| AI | Artificial Intelligence |
| ANGPTL3 | Angiopoietin Like 3 (A protein involved in lipid metabolism) |
| CHA2DS2-VA | Risk stratification score: Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke/TIA/Thromboembolism, Vascular disease, Age 65–74 years |
| CI | Confidence Interval |
| CRISPR | Clustered Regularly Interspaced Short Palindromic Repeats |
| FLNC | Filamin C |
| GLP-1 | Glucagon-Like Peptide-1 |
| HCN4 | Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4 |
| HR | Hazard Ratio |
| LDL | Low-Density Lipoprotein |
| LoDoCo-2 | Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease 2 |
| MYH6 | Myosin Heavy Chain 6 |
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 |
| RBM20 | RNA Binding Motif Protein 20 |
| SCN5A | Sodium Voltage-Gated Channel Alpha Subunit 5 |
| UK | United Kingdom |